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Cognitive deficits in fragile X syndrome (FXS) are
attributed to molecular abnormalities of the brain’s
vast and heterogeneous synapse populations. Un-
fortunately, the density of synapses coupled with
their molecular heterogeneity presents formidable
challenges in understanding the specific contribution
of synapse changes in FXS. We demonstrate power-
ful new methods for the large-scale molecular anal-
ysis of individual synapses that allow quantification
of numerous specific changes in synapse popula-
tions present in the cortex of a mouse model of
FXS. Analysis of nearly a million individual synapses
reveals distinct, quantitative changes in synaptic
proteins distributed across over 6,000 pairwise met-
rics. Some, but not all, of these synaptic alterations
are reversed by treatment with the candidate thera-
peutic fenobam, an mGluR5 antagonist. These pat-
terns of widespread, but diverse synaptic protein
changes in response to global perturbation suggest
that FXS and its treatment must be understood as a
networked system at the synapse level.
INTRODUCTION
Cognitive deficits in neurological diseases are often attributed to
synapse abnormalities (Bhakar et al., 2012; Coghlan et al., 2012;
Garden and La Spada, 2012; Grant, 2012; Sheng et al., 2012).
The understanding of these abnormalities is complicated by
the heterogeneity of the brain’s vast synapse populations (Baye´s
et al., 2011; Emes andGrant, 2012; O’Rourke et al., 2012). Unfor-
tunately, the methods used to quantify synaptic abnormalities in
these diseases are either too narrow (direct recording from single
cells) or too broad (homogenized tissue from entire brain regions)
to capture the expected range and detail of synaptic deficits.
For example, previous studies have used assays of total cellular
protein expression as surrogates of synaptic protein changes
in diseased brains, but it is highly likely that synaptic and total
cellular protein levels are independently regulated. MethodsNethat can capture the expected scope of neurological deficits
with single-synapse resolution are thus needed. Such methods
should facilitate the detailed understanding of disease-wrought
changes in the synapse population (Defelipe, 2011; O’Rourke
et al., 2012) and provide better pharmaceutical targets in normal-
izing the perturbed ecology of the synaptic landscape (Cum-
mings et al., 2013; Henderson et al., 2013).
FXS is a genetic disorder associated with intellectual disability
and is the leadingmonogenic cause of autism. It is caused by the
epigenetic silencing of a single gene, fragile x mental retardation
1 (Fmr1) (Pieretti et al., 1991; Verkerk et al., 1991). The singular
loss of the Fmr1 gene product, fragile X mental retardation pro-
tein (FMRP), leads to the perturbation of a number of highly inter-
connected molecular signaling cascades that underlie a large
number of important neuronal and synaptic processes (Grewal
et al., 1999; Hoeffer and Klann, 2010; Shiflett and Balleine,
2011; Sweatt, 2001; Thiels and Klann, 2001). For example,
mammalian target of rapamycin (mTOR) and extracellular
signal-related kinase (ERK) are implicated in FXS synapse
dysfunction (Bhakar et al., 2012; Gallagher et al., 2004; Osterweil
et al., 2013; Sharma et al., 2010), and they are both well-known
signal transduction hubs that are involved in regulating a number
of neuronal processes including synaptic plasticity, dendritic
development, and local translation. (Grewal et al., 1999; Hoeffer
and Klann, 2010; Kindler and Kreienkamp, 2012; Sweatt, 2001;
Thiels and Klann, 2001). Thus, one would expect a wide range
of synaptic perturbations in FXS that have not been quantified
to date.
The association of abnormal dendritic spine morphology and
density with FMRP loss has been a major focus of FXS research
(Comery et al., 1997; Cruz-Martı´n et al., 2010; Galvez andGreen-
ough, 2005; Galvez et al., 2003; Lauterborn et al., 2013; Nimchin-
sky et al., 2001). Spines are important in that they represent
structural proxies of cortical excitatory synapses (Tada and
Sheng, 2006; Nimchinsky et al., 2002; Segal, 2005; Yuste and
Bonhoeffer, 2001). However, to date, few studies have directly
quantified excitatory synapse changes in FXS. Moreover, previ-
ous studies of dendritic spine density have revealed heteroge-
neous responses to FMRP loss that are age, cell type, and brain
area specific (Cruz-Martı´n et al., 2012; Galvez and Greenough,
2005; Lauterborn et al., 2013; Nimchinsky et al., 2001; Till
et al., 2012; Wijetunge et al., 2014). It is clear, however, that
glutamatergic mechanisms that modulate excitatory synapseuron 84, 1273–1286, December 17, 2014 ª2014 Elsevier Inc. 1273
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et al., 2011; Le Duigou et al., 2011; Gallagher et al., 2004; Huber
et al., 2000; Vinueza Veloz et al., 2012; Zhang and Alger, 2010).
Yet, the full extent and implication of those mechanistic changes
on the synapse population has not been described. Inhibitory
synapses are also affected by FMRP loss, but how their density
or molecular characteristics are changed remains mostly unde-
fined (Adusei et al., 2010; D’Hulst et al., 2009; Gibson et al.,
2008; El Idrissi et al., 2005). The present study is designed to
quantify density and molecular changes, due to FMRP loss, in
both excitatory and inhibitory synapses, with a detailed focus
on excitatory synapse populations.
Progress in defining the molecular dysfunction in Fmr1
knockout (KO) synapses has made FXS one of a few neurodeve-
lopmental diseases with targeted drugs in clinical trials (Berry-
Kravis et al., 2012; Do¨len et al., 2010; Michalon et al., 2012).
Metabotropic glutamate receptor 5 (mGluR5) is a major pharma-
ceutical target for the treatment of FXS in humans (Bhakar et al.,
2012; Do¨len et al., 2010; Robertson, 2013). Antagonists against
mGluR5, including the highly selective compound fenobam
(Berry-Kravis et al., 2009; Vinueza Veloz et al., 2012; de Vrij
et al., 2008), are effective in alleviating some behavioral and
neuronal perturbations caused by FMRP loss in mice (Auerbach
et al., 2011; Do¨len and Bear, 2008; Michalon et al., 2012; Wije-
tunge et al., 2008). However, antagonism of mGluR5 leads to
heterogeneous changes in the expression of long-term depres-
sion, long-term potentiation, and homeostatic plasticity in a re-
gion- and layer-specific manner in the cortex (Anwyl, 2009; Hu
et al., 2010; Tsanov and Manahan-Vaughan, 2009; Ueta et al.,
2008). Such complexity of mGluR5 antagonism greatly compli-
cates mechanistic interpretation of mGluR5 function in FXS
and suggests a diversity of pharmacological efficacy that has
not yet been experimentally verified.
Thus, to better quantify the synaptic etiology of FXS and bring
new understanding to its treatment, systematic analysis of the
effects of FMRP loss on the heterogeneous circuit and synaptic
elements of the brain is needed. To this end, we combined the
subdiffraction, molecular imaging capabilities of array tomogra-
phy (AT) (Micheva and Smith, 2007; Wang and Smith, 2012) with
a computational synapse classification algorithm. This algorithm
allows for the analysis of molecularly defined synapse classes
that belong to specific functional circuits. This analysis gener-
ated over 6,000 synapse metrics incorporating over 1 million
excitatory and inhibitory synapses of cortical-cortical and thala-
mocortical neural circuits distributed across layers 4 and 5 of
the mouse somatosensory cortex. The single-synapse-level res-
olution combined with the numeric and spatial coverage of the
data set allowed us an unprecedented system-level view of the
fine scale, quantitative changes in the synapse population that
are mediated by systemic loss of FMRP and its pharmacological
rescue by fenobam.
We found that the loss of this single gene product causes a
formidable transformation of the synaptic landscape in the KO
cortex. Fmr1 loss generates distinct synaptic phenotypes across
the entire synapse population. The expression of these pheno-
types depends on the circuit and the cortical layer. For instance,
the density of total excitatory synapses is elevated in layer 4,
while it is unchanged in layer 5. However, in layer 5, synapses1274 Neuron 84, 1273–1286, December 17, 2014 ª2014 Elsevier Incof the thalamocortical circuit are specifically decreased. More-
over, the response of these synaptic phenotypes to fenobam
treatment is also specific to the molecular composition and
cortical layer of the synapses studied, and while this study dem-
onstrates that fenobam treatment can be highly effective in
rescuing many synaptic perturbations, its efficacy can be limited
to specific synaptic subsets. For example, themolecular compo-
sition of layer 4 thalamocortical synapses is not effectively
rescued by fenobam treatment, while layer 5 thalamocortical
synapses are. Thus, the data in this work illustrate that the diver-
sity of neural circuits, cell types, and synapse classes react
distinctly to global perturbations, even if those perturbations
are initiated by a single ubiquitous gene or drug. The results of
this study demonstrate the complex problems that challenge
our understanding of neurological diseases and their treatments,
but this study also provides new methodology to solve these
problems and demonstrates how data can be acquired to
constrain and describe disease-mediated synaptic changes at
a systems level. Thus, this study provides a unique profile of
system-level synaptic deficits in FXS and presents methods of
molecularly constrained synapse analysis that can generate
quantitative metrics for the evaluation of synapse population
changes and their rescue by therapeutics.
RESULTS
AT Enables Robust Computational Classification of
Cortical Synapses
AT provides spatially multiplexed protein data that allow for the
identification of synapses through the correlated localization of
synaptic molecules (Figure 1; Figure S1 available online). For
example, glutamatergic synapses can be found by the apposi-
tion of postsynaptic density 95 (PSD95), synapsin-1 (SYN), and
a vesicular glutamate transporter (VGluT) (Figure 1B, white ar-
rowheads). GABAergic synapses can be found by the apposition
of gephyrin (GPHN), vesicular GABA transporter (VGAT), and
glutamate decarboxylase (GAD) (Figure 1B, yellow arrowheads).
Each of our data sets contains hundreds of thousands of such
protein localizations (Figures 1 and S1). Computational methods
are therefore necessary to quantify the synaptic information con-
tained in these data sets.
We used the local orientation and distance of synaptic protein
puncta in conjunction with consensus structural characteristics
of a cortical synapse (De Camilli et al., 1983; Chen et al., 2008;
Heuser and Reese, 1977; Hunt et al., 1996) to classify synapses
based on their molecular orientation and composition. Specif-
ically, punctum objects are segmented using a thresholded con-
nected-components analysis. Then, excitatory synapse classifi-
cation is initiated by computing a local-synapse vector between
the centers of mass of a postsynaptic PSD95 punctum and a
presynaptic SYN punctum (Figure 1C; also see Experimental
Procedures for addition details). The magnitude of that synaptic
vector, which is the distance (d1 in Figure 1C) between PSD95
and SYN centers, is used to define a unique colocalization
sphere for each candidate synapse. Any protein centers from
other protein channels that fall within this sphere are considered
colocalized to the candidate synapse. The verification of candi-
date excitatory synapses uses a third protein channel of known.
Figure 1. Detection and Classification of
Synapses from Multichannel Array Tomo-
graphic Volume Images
(A) Composite maximum intensity projection illus-
trating the density of synaptic protein puncta in
layer 4 cortex. Blue, DAPI; green, YFP; cyan,
PSD95; red, SYN; and yellow, VGluT1. Scale bar,
10 mm.White arrowhead points at a dendritic spine
with a glutamatergic VGluT1-containing synapse.
Yellow arrowhead points at a dendrite shaft
GABAergic synapse. Projected volume: 0.3 mm by
0.3 mm by 2 mm.
(B) Zoomed-in views of dendrite segment marked
by white box in (A). Each box contains only one
protein marker as labeled in the lower left of each box. Note the orientation of the synaptic markers, where postsynaptic and presynaptic molecules are spatially
organized in a specific pattern. Also, note how the synapse present on the spine can be classified as a VGluT1 synapse based on the presence of VGluT1 and the
absence of VGluT2.
(C) Schematic of distance calculationsmade for synapse analysis superimposed on 2D projection of a volumetric rendering of the excitatory synapse in ([B], white
arrowhead). Distance between the center of mass from PSD95 and SYN (d1) is used to generate a colocalization sphere for the determination of protein co-
localization (e.g., if the distance of a VGluT1 center to PSD95 [d2] is smaller than [d1], then that punctum is considered colocalized to the candidate synapse). The
verification of the candidate synapse represented by the PSD95-to-SYNpair is made if the distance of the VGluT1 center to PSD95 (d2) is longer than the distance
of the VGluT1 center to SYN (d3), signifying that the VGluT1 is presynaptic.
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(VGluT1), so that the representative ratification of a VGluT1 syn-
apse requires a presynaptic VGluT1 center to be closer to SYN
than PSD95 (Figure 1C). This logic also holds for inhibitory syn-
apses with postsynaptic GPHN, presynaptic VGAT, and GAD
as the third presynaptic inhibitory marker. This method gener-
atesmolecularly defined synapse classes that are robust against
variations in image segmentation thresholds (Figures S2A–S2I)
and consistent with human classified data (Figure S2J) (Micheva
et al., 2010).
Using analogous methods with additional proteins, 25 molec-
ularly defined synapse classes were generated (Figure 2A) in 34
mice across four conditions (wild-type [WT], Fmr1 KO, fenobam-
treated WT, and fenobam-treated Fmr1 KO). These 25 synapse
classes form a distinct hierarchy that represent specific molecu-
lar combinations of proteins in the data set that were determined
a priori to be of interest in FXS etiology. Excitatory and inhibitory
synapse types form the basis of all 25 classes. Excitatory synap-
ses are further divided by whether they contain VGluT1, VGluT2,
or both proteins. These excitatory classes represent genetically
defined synaptic types that do not transit between each other
(Figure S3) (Fremeau et al., 2001; Graziano et al., 2008; Herzog
et al., 2001; Kaneko and Fujiyama, 2002; Nahmani and Erisir,
2005; Nakamura et al., 2005). These genetically defined excit-
atory synapse classes are further subdivided by the combination
of other molecular markers in those synapses, such as synapto-
podin (SYNPO) and Fragile X-related proteins 1 and 2 (FXR1P
and FXR2P). These molecularly defined subclasses represent
more plastic synapse types. For example, SYNPO synapses
represent mature dendritic spines whose identity can be modi-
fied by learning or other environmental factors (Deller et al.,
2000, 2003; Holbro et al., 2009; Segal et al., 2010; Vlachos
et al., 2009).
We used these methods to analyze layers 4 and 5 of the adult
(4-months-old) mouse somatosensory cortex (Figure 2B). These
two cortical layers were selected because sensory information
processing is a known behavioral deficit in FXS patients andNeFmr1 KO mice (Baranek et al., 2008; Hoeft et al., 2010; Kogan
et al., 2004; Ventura et al., 2004; Yan et al., 2004). Layers 4
and 5 represent, respectively, the majority of direct thalamic-
sensory input and the integrated cortical network output of the
cortex (Aronoff et al., 2010; Douglas and Martin, 2004; Feld-
meyer and Sakmann, 2000; Lu¨bke and Feldmeyer, 2007; Schu-
bert et al., 2007). In total, over a million synapses were analyzed
across four animal conditions generating over 6,000 potential
pairwise metrics.
Effects of Fmr1 KO and Fenobam Treatment Are Layer
and Circuit Specific
A layer- and circuit-specific analysis of cortical volumetric syn-
apse density changes in response to FMRP loss is currently un-
available. Therefore, we directly compared the average ratios of
Fmr1 KO and WT excitatory synapse density from layers 4 and 5
of the mouse somatosensory cortex (Figure 3). Ratios are used
because tissue from KO and WT brains were paired starting at
fixation to reduce variability caused by tissue processing, immu-
nohistochemistry, and imaging (see Experimental Procedures).
In layer 4 the density of total excitatory synapses is significantly
elevated in KO mice, even after adjustment for multiple compar-
isons using Benjamini-Hochberg false discovery rate calcula-
tions (q < 0.05; see Experimental Procedures). In contrast, the
total excitatory synapse density in layer 5 is not significantly
different between KO and WT (q > 0.05; Figure 3A).
To study the changes in excitatory synapse density in more
detail, we subclassified excitatory synapses by their VGluT
composition. The two major cortical VGluTs (VGluT1 and
VGluT2) are ideal for the discrimination of excitatory synapses
because they represent markers of specific cortical circuits,
such that VGluT1 is expressed in the majority of cortical-cortical
synapses and VGluT2 is expressed in the majority thalamocort-
ical synapses. (Fremeau et al., 2001; Graziano et al., 2008;
Herzog et al., 2001; Kaneko and Fujiyama, 2002; Nahmani and
Erisir, 2005; Nakamura et al., 2005). This class-specific analysis
uncovers specific variation in of Fmr1 KO synapse densitiesuron 84, 1273–1286, December 17, 2014 ª2014 Elsevier Inc. 1275
Figure 2. Cortical Layers, Synapse Classes, and Synaptic Proteins Analyzed in This Study
(A) Schematic representation of synapse classes. Blue circle represent the colocalization sphere. VGluTn, VGluT1 and VGluT2. FXRn, FXR1 and FXR2.
(B) Cortical Layers 4 and 5 are selected for analysis because sensory processing deficits are important behavioral abnormalities seen in FXS. Image: YFP, green;
acetylated tubulin, blue; and SYN, red.
(C) Table of proteins discussed in this paper and their known synaptic function.
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Figure 3. Density Comparison of Synapses Reveals Layer- and Class-Specific Response to FMRP Loss and Fenobam Treatment
(A–I) Average density ratio of KO versus WT synapses from paired mice tissue (see Experimental Procedures). Paired tissue is used to reduce variability in tissue
processing and immunolabeling.
(A) Density ratios of KO/WT for the total excitatory synapse population in layers 5 and 4. Layer 4 synapse density is increased in the KO, but in not layer 5. (Insets)
The densities of each individual KO/WT pairs are plotted (n = 6 pairs).
(B) Density ratios for layer 5 VGluT synapse classes and their plotted individual densities. There is a specific decrease in VGluT2 synapse density in layer 5.
(C) Density ratios for layer 4 VGluT synapse classes and their plotted individual densities. Synapse density is increased in all classes.
(D) Density ratios of fenobam-treated KO (FKO)/WT for the total excitatory synapse population in layers 5 and 4 (n = 6 pairs). Fenobam rescues layer 4 density
increases in KO.
(E) Density ratios (FKO/WT) of layer 5 VGluT synapse classes. Fenobam normalizes the specific VGluT2 synapse density increase in layer 5.
(F) Density ratios of Layer 4 VGluT synapse classes. Fenobam normalizes density increases, except for VGluT1 and 2 class synapses.
(G–I) Density ratios of fenobam-treated WT (FWT)/WT for the total excitatory synapse population in layers 5 and 4 (n = 5 pairs). Fenobam does not induce
significant change in synapse density in the WT. Error bars, SE. Significance is calculated using paired t tests, and the p values are adjusted via Benjamini-
Hochberg false discovery rate (FDR) test. q < 0.05.
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apses, unlike layer 5 total excitatory synapse density, is signifi-
cantly decreased, while all excitatory synapse classes areNeelevated in layer 4, in agreement with layer 4 total synapse den-
sity increase (q < 0.05; Figures 3B and 3C). This demonstrates
that FMRP loss differentially affects synapses in thalamocorticaluron 84, 1273–1286, December 17, 2014 ª2014 Elsevier Inc. 1277
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layer and class specific.
To explore the extent to which fenobam treatment reverses
these circuit- and layer-specific effects of Fmr1 KO, we orally
administered fenobam (100 mg per kg body weight) to Fmr1
KO mice for 2 weeks (see Experimental Procedures for more
details). Comparison of these animals with paired WT animals
(Figures 3D–3F) revealed that, with the exception of layer 4
VGluT1/2 synapses, fenobam treatment rescued density
changes across all other synapse classes in both cortical layers
of the KO (Figures 3E and 3F). Layer 4 VGluT1/2 synapse den-
sity, which was significantly elevated in the KO, was reduced by
fenobam, but this reduction led to a significant density decrease
of this synapse class (q < 0.05; Figures 3E and 3F). Furthermore,
control tests of fenobam in WT animals showed that by itself fe-
nobam did not significantly modify synapse density in these
synapse classes, demonstrating that the fenobam effects are
specific to the KO (Figures 3G–3I). This shows that fenobam
can be highly effective in treating many synapse density deficits
mediated by FMRP loss. However, drug treatment may produce
its own specific synaptic changes as in layer 4 VGluT1/2 syn-
apse class.
Cellular and Synaptic Protein Levels Are Not Always
Correlated
Wenext assessedwhether synaptic protein content reflects total
cellular protein expression. To accomplish this, we compared
the density and integrated intensity of total and synaptic protein
puncta. Together, the density and integrated intensity metrics
represent a quantitative measure of the relative protein content
present in the tissue volume. In layer 4, neither the density nor
the integrated intensity of total VGluT2 puncta are significantly
changed between KO and WT (q > 0.05; Figures S3B and S4I).
Nonetheless, the density of layer 4 VGluT2-containing synapses
is significantly increased in the KO (q < 0.05; Figure 3C). Thus,
the layer 4 VGluT2 synapse density increase mediated by
FMRP loss is not due to a total cellular increase in VGluT2 protein
level. This reveals that synapse density is not necessarily con-
nected to total protein levels. Moreover, total and synaptic pro-
tein level changes can also be disconnected. For example, total
VGluT1 protein density and integrated intensity is unchanged in
the KO (Figures S3B and S4I), while KO VGluT1 synapse density
and integrated intensity is increased (Figures 3C and S4I),
revealing a specific increase in synaptic VGluT1 protein but not
in total cellular VGLuT1 protein levels.
In layer 5 results are again different. In the KO, the total VGluT2
punctum density is decreased (q < 0.05, Figure S3A), without a
change in integrated intensity (Figure S4A), matching the signif-
icant reduction in the density of KO VGluT2-containing synapses
(Figure 3B). This represents a case in which synapse and total
protein levels are in agreement. Layer 5 VGluT1 synapse density
is also unchanged (Figure 3B) in agreement with layer 5 VGluT1
total protein punctum density in Fmr1 KO (Figure S3A), but
the integrated intensity of layer 5 synaptic VGluT1 puncta is
increased in the KO, unlike the total VGluT1 punctum integrated
intensity, which is not significantly different fromWT (Figure S4A).
This demonstrates that FMRP loss specifically increases
the VGluT1 protein content of synapses without affecting the1278 Neuron 84, 1273–1286, December 17, 2014 ª2014 Elsevier Incnumber of VGluT1 synapses and the protein content of cellular
VGluT1 puncta, in layer 5. Thus, our data reveal an imperfect cor-
relation between total cellular protein levels and synaptic protein
levels and demonstrate the need for synapse-specific analysis,
as compared to tissue-specific analysis, to resolve synaptic pro-
tein differences mediated by cellular perturbations.
FMRP Loss Induces Fenobam-Reversible Decrease in
SYNPO-Containing Mature Dendritic Spines
SYNPO is a key regulator of mGluR-mediated spine plasticity
and a marker of mature dendritic spines (Deller et al., 2000,
2003; Holbro et al., 2009; Segal et al., 2010; Vlachos et al.,
2009). This establishes SYNPO as protein of substantial interest
for FXS-mediated synaptic phenotypes (Comery et al., 1997; Do¨-
len and Bear, 2008; Galvez et al., 2003; Vinueza Veloz et al.,
2012; Zhang et al., 2009). In Fmr1 KO animals, there is an overall
decrease in total SYNPO punctum density in both layers (Fig-
ure S3), while their integrated punctum intensity is not changed
(Figures S4A and S4I). This reveals a general decrease in the
expression of SYNPO protein in the KO. Yet, the total SYNPO-
containing synapse density is unaffected in both layers (q >
0.05, Figure 4A), suggesting that the overall density of SYNPO-
containing spines is stable in spite of the decrease in total protein
levels.
Significant effects of FMRP loss, however, are unmasked by
the breakdown of synapse classes. In layer 5, SYNPO-contain-
ing VGluT2 synapses are significantly reduced in the KO (q <
0.05; Figure 4B), consistent with the overall loss of layer 5 VGluT2
synapses in the KO (q < 0.05; Figures 3B and S3A). In layer 4
of KO mice, SYNPO-containing VGluT1 synapse density is
depressed compared to WT (q < 0.05; Figure 4B) even though
the total layer 4 VGluT1 synapse density is increased (Figure 3C).
This reveals a selective decrease in SYNPO-containing layer 4
VGluT1 synapses in response to FMRP loss, suggesting that
there is a specific decrease in layer 4 mature SYNPO-containing
dendritic spines that receive cortical input.
Thus, the global loss of FMRP mediates alterations of SYNPO
synapse density that is highly population specific and layer spe-
cific. The oral application of fenobam is effective in rescuing the
loss of total SYNPO punctum (q < 0.05; Figure S3) and class-
specific SYNPO synapse density changes in KO animals across
both layers (q > 0.05; Figures 4C and 4D). This suggests that
mGluR5 signaling is an important regulator of the cellular and
synaptic expression of SYNPO, which is further reinforced by
data generated by the fenobam treatment of WT animals. Anal-
ysis of fenobam-treatedWT animals reveals that while layer 4 to-
tal SYNPO synapse density is not increased, layer 5 total SYNPO
synapse density is significantly elevated (q < 0.05; Figure 4E),
and this increase is primarily due to a significant increase in layer
5 SYNPO VGluT1 synapses (q < 0.05; Figure 4F). This concurs
with the data suggesting that SYNPO is an important regulator
of mGluR5-mediated signaling (Deller et al., 2000, 2003; Holbro
et al., 2009; Segal et al., 2010; Vlachos et al., 2009) and that
perturbation of mGluR5 signaling affects the synaptic localiza-
tion of SYNPO. Moreover, the fact that the loss of FMRP in layer
5 abolishes this fenobam-mediated increase in SYNPO VGluT1
synapses means that FMRP action is directly involved in this
mGluR5 mediated increase..
Figure 4. FMRP Loss Induces Fenobam-
Reversible Changes in SYNPO Containing
Mature Dendritic Spines
(A) Density ratios of KO/WT synapses containing
SYNPO, a marker of mature dendritic spines,
reveal no significant change in total SYNPO syn-
apse density (n = 6 pairs).
(B) Analysis of specific synaptic classes reveals
significant synapse density changes mediated by
FMRP loss in layer 4 VGluT1 synapses and layer 5
VGluT2 synapses.
(C and D) Fenobam treatment normalizes to WT
SYNPO-containing synapse density across all
classes (n = 6 pairs).
(E) Fenobam application in WT animals induces a
density increase in layer 5 synapses (n = 5 pairs).
(F) Fenobam-induced SYNPO synapse density
increase is specific to VGluT1 class synapses.
Error bars, SE. Significance is calculated using
paired t tests, and the p values are adjusted via
FDR test. q < 0.05.
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VGluT2 synapse density levels (Figure 4F), which suggest that fe-
nobam directly rescues FMRP-loss-mediated SYNPO VGluT2
synapse loss (Figures 4B and 4D). Layer 4 again presents a
different scenario: layer 4 SYNPO VGluT1 synapses are also
elevated in WT fenobam-treated animals (q < 0.05; Figure 4F),
even though the total SYNPO synapse density in layer 4 is not
affected (Figure 4E). This increase of layer 4 SYNPO VGluT1 syn-
apses in fenobam-treated WT animals suggests that the normal-
ization of layer 4 SYNPO VGluT1 synapse density in the KO (Fig-
ure 3F) might not be a direct rescue by fenobam but a potential
occlusion of the KO-mediated decrease by the fenobam-
induced synapse density increase (Figures 4B and 4D). These
data reveal that the specificity and efficacy of drug action is
also subject to variation dependent upon synapse class and
cortical layer.
Levels of FXR1P and 2P Expression Are Differentially
Impacted by FMRP KO and Fenobam Rescue
FXR1P and FXR2P are nearly structurally identical autosomal ho-
mologs of FMRP (Adams-Cioaba et al., 2010; Tamanini et al.,
1997, 1999). FXRs are known to form heteromeric complexes
with FMRP in neurons (Ceman et al., 1999; Christie et al.,
2009; Tamanini et al., 1999). Unfortunately, their involvements
in FXS and their synaptic function remain largely unknown. We
find the response of FXR2P to FMRP loss to be highly layer spe-
cific. FXR2P synapse density and total puncta density are bothNeuron 84, 1273–1286, Dedramatically decreased in layer 5 KO an-
imals (q < 0.05; Figures 5A and S3A) but
not in layer 4 (q > 0.05; Figures 5A and
S3), and this reduction is entirely nonre-
sponsive to fenobam rescue (q < 0.05,
Figure 5B). These data suggest that in
layer 5, FXR2P expression is highly
dependent on the presence of FMRP
and is independent of mGluR5 signaling.
In agreement with the density data, layer5 integrated intensity metrics for layer 5 VGluT1 synapses reveal
a decrease in FXR2P protein content in those synapses (Fig-
ure S4A). This synaptic decrease of FXR2P protein content, how-
ever, is again synapse class dependent, as FXR2P puncta levels
are increased in KO VGluT2 synapses (Figure S4A) even though
VGluT2 synapse density is dramatically reduced (Figure 5A). This
illustrates that in layer 5 fewer VGluT2 synapses contain FXR2P,
but when they are found at those synapses, they are there at
greater amounts. Also in agreement with the notion that mGluR5
signaling does not affect FXR2P expression, fenobam treatment
of WT animals did not affect FXR2 synapse densities in either
layers 4 or 5 (Figure 5C).
The density of FXR1P-containing synapses does not respond
to FMRP loss in either cortical layer (q < 0.05; Figure S5) and is
also independent of mGluR5 signaling (Figure S5). FXR1P total
and synaptic integrated intensity is also unaffected in Fmr1 KO
(Figure S4). In layer 5, however, the total puncta density of
FXR1P is elevated by FMRP loss (Figure S3). This increase can
be rescued by fenobam treatment (q < 0.05; Figure S3A), which
suggests that layer 5 mGluR5 signaling regulates cellular FXR1P
protein levels, but not synaptic FXR1P levels.
Fenobam Rescues Fmr1 KO-Mediated Inhibitory
Synapse Increases
TheanalysisofGPHN-containingGABAergic synapses in layers4
and 5 of the cortex reveals a significant density increase in
inhibitory synapses of both layers of the KO (q < 0.05; Figure 6A).cember 17, 2014 ª2014 Elsevier Inc. 1279
Figure 5. FMRP Loss Specifically Impacts Layer 5 FXR2P-Contain-
ing Synapse Density Independent of mGluR5 Signaling
(A) FXR2P-containing synapse density is significantly depressed in layer 5
cortex of Fmr1 KO in nearly all synapse classes in the study (n = 6 pairs). Layer
4 FXR2P synapses are not perturbed.
(B) This effect is insensitive to fenobam treatment (n = 6 pairs).
(C) Fenobam treatment in WT animals does not affect FXR2P synapses in
either layer 4 or 5 (n = 5 pairs). Error bars, SE. Significance is calculated using
paired t tests, and the p values are adjusted via FDR test. q < 0.05.
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Diverse Synaptic Response to Fmr1 KO and Its RescueThis density increase maintains the ratio of GABAergic synapse
density to the total glutamatergic synapse density, as the
percentage of GABAergic synapses to the total synapse num-
ber remains the same in both WT and KO (Figure 6B). This
suggests that the GABA system may be responding to changes
in the glutamatergic system, which is a synapse plasticity
phenomenon that is well documented in sensory cortices (Li
et al., 2009; Maffei et al., 2006; Micheva and Beaulieu, 1995).
Fenobam treatment provides further support for the role of
glutamate signaling in this inhibitory synapse density increase,
as it rescues the GABAergic synapse density increase in layer
4, and reduces the density of layer 5 GABAergic synapses
to below WT levels (Figure 6A). This fenobam effect is specific
to the FMRP-mediated mechanisms, as fenobam treatment
in WT animals did not affect GABAergic synapse densities
(Figure 6A).1280 Neuron 84, 1273–1286, December 17, 2014 ª2014 Elsevier IncFmr1 KO Alters the Molecular Composition of Synapse
Populations
Our findings indicate that Fmr1 KO impacts diverse synapse
populations differentially across a wide range of measures. Pair-
wise comparisons, while informative, do not readily provide a
quantitative, statistical measure of the integrated changes
occurring in the data set. Thus to provide a more integrated
approach to evaluate the synapse data, multivariate logistic re-
gressions can be used to reveal system-level trends in our mea-
surements of synaptic protein level (puncta intensity and puncta
integrated intensity) and synaptic protein structure (puncta vol-
ume and punctum distance from PSD) (Hosmer and Lemeshow,
2000). Logistic regressions can generate functions that quantita-
tively relate changes in the molecular features of a synapse (the
independent variables) to the probability of that synapse being
KO or WT (the binomial dependent variable, KO = 1, WT = 0;
see Experimental Procedures).
The application of this regression on 57,480 WT and 66,702
KO synapses, pooled from five animals of each genotype, gen-
erates a set of probabilities that represents the likelihood of
whether a synapse is KO or WT based on the molecular mea-
sures associated with each synapse. Thus, the histograms
generated from these probabilities visually represent the quanti-
tative, statistical difference between KO and WT as defined by
molecular properties of proteins associated with each popula-
tion of synapses. Assessing these histograms it is clearly evident
from the separation of peaks and the significantly different distri-
butions (Kruskal-Wallis p < 0.01; Figures 7A, 7B, 7E, and 7F) that
both layer 5 and layer 4 KO synapse populations are molecularly
different from theirWT counterparts (Figure 7). Moreover, regres-
sion analysis shows that layer 5 KO andWT synapse populations
are more separated from each other than layer 4 synapse popu-
lations (Figure 7). However, pairwise synapse density measures
demonstrated that layer 4 synapses are more affected by FMRP
loss than those in layer 5 (Figure 3). This illustrates that single
metrics cannot fully describe the synaptic deficits seen in Fmr1
KO mice and that synapse-modifying mechanisms engaged by
FMRP loss vary across cortical layers. This layer-specific differ-
ence carries over to the response of the synapse populations to
fenobam. Layer 5 synapse molecular features in Fmr1 KO ani-
mals are fully rescued by fenobam treatment (Kruskal-Wallis
p < 0.01; Figure 7C), while in layer 4, the change between KO
and fenobam-treated KO synapse populations is much more
modest (Figure 7G). Fenobam treatment in WT animals did shift
the synapse population to a more WT distribution in layer 5 but
not in layer 4 (Figures 7D and 7H). This again reaffirms the differ-
ences in the population response to fenobam of synapses in
both layers.
To verify the fidelity of the regression it is important to show
that the regression function can accurately categorize new
data based on its animal background. We demonstrated this
by applying the regression function to 23,448 WT and 21,160
KO synapses from a pair of KO/WT animals that were randomly
excluded from building the regression function. The correct
categorization of these naive synapse populations by the regres-
sion clearly demonstrates that by synaptic molecular features
alone the animal background of the imaged tissue can be diag-
nosed (Figures S6A and S6B). This not only validates the fidelity.
Figure 6. mGluR5-Sensitive Increase in
GABAergic Synapse Density in Fmr1 KO
(A) GABAergic synapse density in both layers 5 and
4 are elevated in Fmr1 KO animals (n = 6 pairs).
Fenobam treatment normalizes to WT layer 4
GABAergic synapse density increase, while it re-
verses layer 5 GABAergic synapse density in-
crease to a significant decrease (n = 6 pairs).
(B) GABAergic synapses as a percent of total
classified synapse is not changed. This suggests
that GABAergic synapse density is changing in
response to glutamatergic synapse density to
maintain a specific ratio.
(A and B) Fenobam treatment inWT does not affect
total GABAergic synapse density (n = 5 pairs). Error
bars, SE. Significance is calculated using paired t
tests, and the p values are adjusted via FDR test.
q < 0.05.
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Diverse Synaptic Response to Fmr1 KO and Its Rescueof the regression but also suggests that it is possible to diagnose
the disease phenotype of a biopsy-size, sub-cubic millimeter
piece of cortex based solely on its synapse protein metrics.
Finally, looking at the measures that the regression found
most informative in determining whether a synapse is KO or
WT, it is clear that the volume and distance of punctum from
PSD measures are the most informative (Figure S6C; Table
S1). This suggests that the size distribution of the synapse pop-
ulation in the KO animals is different from WT, which is an inter-
esting observation in that the prevailing idea of FXS synapse
dysfunction involves abnormal synapse plasticity and matura-
tion (Comery et al., 1997; Do¨len et al., 2007; Galvez and Green-
ough, 2005; Huber et al., 2002; Nimchinsky et al., 2001), which,
if it is pervasive, should lead to system-level synapse size
changes.
Regression Analysis of Synapse Classes Reveals
Circuit-Specific Efficacy of Fenobam
Regression statistics can be generated on a synapse class level.
This analysis confirms that layer 5 synapse molecular properties
are more perturbed by FMRP loss than layer 4 synapse proper-
ties (Figure 8A). Fenobam treatment is also again more effective
in layer 5 than in layer 4 (Figures 8A and 8B). Interestingly, VGluT1
synapse classes aremore responsive to fenobam treatment than
VGluT2 synapse classes (Figures 8A and 8B), and this is espe-
cially apparent in layer 4 (Figure 8B). Furthermore, in layer 4,
this class-specific regression analysis reveals that synapses
that contain FXR2P appear more WT than synapses that do
not (Figures 8A and 8B), supporting the well-documented wors-
ening of behavioral phenotypes in FXR2P and FMRP double KOs
(Spencer et al., 2006; Tamanini et al., 1999; Zhang et al., 2009),
and indicates that FXR2P can compensate in part the loss of
FMRP. These results further reaffirm that synapse populations
differentially respond to global perturbations such as FMRP
loss or drug treatment. They demonstrate that this type of anal-
ysis can quantitatively reveal the class-specific efficacy of ther-
apeutic compounds and that synapse specific analysis has the
potential for assessing often complex response of the synapse
population in diseases and its attempted treatment.NeDISCUSSION
Hypothesized etiologies of mental and neurological disorders
often involve abnormalities of molecular synapse phenotypes,
but technical limitations have greatly restricted previous efforts
to test such hypotheses directly and quantitatively. In particular,
the heterogeneity of synapse populations in themammalian CNS
demands that decisive analysis be carried out at the level of in-
dividual synapses or individual synapse classes (Grant, 2012;
O’Rourke et al., 2012). Unfortunately, the small size and dense
intermixture of diverse synapse populations has resisted such
analysis. Here we demonstrate the use of a unique approach
to single-synapse analysis, based on AT and statistical image
analysis methods, to explore synapse abnormalities in a mouse
model of human fragile X syndrome and to assess differential im-
pacts of a candidate therapeutic compound on these synapse
subsets.
The work described in this paper reveals that synapse pheno-
types associatedwith FMRP loss are diversified by cortical layer,
circuit type, and molecular composition of synapses. We show
that cellular level changes of proteins can fail to reflect changes
in levels of that same protein asmeasured in synapses. This sug-
gests that synapse level analysis is essential for the determina-
tion ofmolecular changes in synapses in response to tissue-level
perturbation. For example, the increase in layer 4 VGluT2 syn-
apse density in FMR1 KO animals is independent of total VGluT2
protein levels, and the overall decrease in cellular SYNPOprotein
level does not affect the density of synapses that contain
SYNPO. These data demonstrate that measuring synaptic pro-
tein changes in response to system-level perturbations requires
single synapse analysis.
The broad scope of our data combined with the synaptic and
circuit-level analysis afford us a unique perspective on diverse
mechanisms that affect synapse change in response to global
FMRP loss. For instance, the observations that layer 5 synapse
protein properties in Fmr1 KO are highly perturbed while layer
5 synapse density is essentially unchanged coupled with the
opposite observations in layer 4 suggest different population-
level mechanisms acting in the two layers in response to theuron 84, 1273–1286, December 17, 2014 ª2014 Elsevier Inc. 1281
Figure 7. Logistic Regression Analysis ofWT, KO, and FKO Synapses Reveals Population Level Shifts inMolecular Features of Synaptic Pro-
teins
(A–H) Population histograms of synapse probabilities of synapses being KO, calculated by regression analysis using synaptic protein feature values for each
synapse (KO = 1; WT = 0).
(A and B) Layer 5 population distributions are highly separated. Thus, molecular features of layer 5 KO synapses as a population are clearly distinct from Layer 5
WT synapses.
(A) Layer 5 WT synapse population. (Average probability of being KO = 36%, n = 22,679 synapses, 5 pairs animal.)
(B) Layer 5 KO synapse population. (Average probability of being KO = 72%, n = 33,846 synapses, 5 pairs animal.)
(C) Layer 5 FKO synapse population. Fenobam treatment rescues change in KO synapse molecular features. (Average probability of being KO = 29%, n = 70,000
synapses, 6 pairs animal.)
(D) Layer 5 WT synapse population is not affected by fenobam treatment. (Average probability of being KO = 25%, n = 60,372 synapses, 5 pairs animal.)
(E and F) Layer 4 KO and WT synapse populations, while significantly different, are less so than layer 5 synapse populations.
(E) Layer 4 WT synapse population. (Average probability = 39%, n = 34,801 synapses, 5 pairs animal.)
(F) Layer 4 KO synapse population. (Average probability = 56%, n = 32,856 synapses, 5 pairs animal.)
(G) Layer 4 FKO synapse population. (Average probability = 54%, n = 58,408 synapses, 6 pairs animals.)
(H) Layer 4 WT synapse population is not affected by fenobam treatment. (Average probability of being KO = 42%, n = 95,482 synapses, 5 pairs animal.)
Statistical comparison of KO versus WT, FKO versus WT, and KO versus FKO distributions by Kruskal-Wallis are significant (p < 0.01).
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Diverse Synaptic Response to Fmr1 KO and Its Rescueloss of FMRP. Layer 4 circuits appear to engage circuit level
plasticity by increasing the number of synaptic contacts, leaving
individual synapses more similar to WT, while layer 5 circuits
appear to engage synapse-level plasticity, thus altering synaptic
protein properties without significantly modulating the number
of synaptic contacts. Another example is the responsiveness
of the GABA system to glutamatergic synapse density change.
GABAergic synapses were elevated in the KO, which maintained
theWTGABAergic to glutamatergic synapse density ratio. Feno-
bam, a glutamate receptor antagonist that rescues glutamate
synapse density changes in the KO, is also able to rescue
GABAergic synapse density changes. These data are consistent
with the allosteric regulation of GABA transmission by changes in
glutamate signaling, even though we cannot fully discount the
direct action of mGluR5 on GABAergic synapses.
Our data also reveal that global loss of FMRP does not affect
all cortical layers and synaptic circuits similarly. We show that
there is an increase in thalamic synapses in layer 4 of Fmr1 KO
animals, while there is a decrease in layer 5 thalamic synapse
density in the KO. This suggests a change in the balance of tha-
lamocortical input into the cortex, which could be mediated by1282 Neuron 84, 1273–1286, December 17, 2014 ª2014 Elsevier Inceither local changes in synapse density or long-range wiring def-
icits. Meanwhile, layer 5 VGluT2-containing thalamic synapses
are more perturbed, as measured by molecular features, than
layer 4 thalamic synapses. This further suggests that layer 5
thalamic input is more affected by FMRP loss than layer 4
thalamic input, which is interesting in light of recent findings
that suggest layer 5 thalamocortical input represents a more
direct path of information transmission from the sensory modal-
ities through the cortex by bypassing the tradition model of
columnar cortical information processing (Constantinople and
Bruno, 2013). This suggests that this mode of direct information
transmission might be more degraded in Fmr1 KO mice and
perhaps in FXS patients as well. This represents a potential
mechanism for sensory information processing deficits caused
by FMRP loss that requires further investigation.
The resistance of thalamocortical VGluT2-containing synap-
ses to fenobam treatment, as revealed by the regression anal-
ysis, coupled with the knowledge that thalamic neurons selec-
tively express FMRP in axon terminals (Akins et al., 2012;
Christie et al., 2009) and that this presynaptic FMRP expression
is enriched in development (Akins et al., 2012) suggest a role in.
Figure 8. Class-Specific Regression Values
Reveal Layer and Class-Specific Efficacy of
Fenobam Treatment and Compensatory
Effects of FXR2P
(A) Graph of average probability of being a KO for
individual synapse classes in layer 5 of the cortex.
An average probability that is closer to 1 means the
population is closer to KO by molecular features.
An average that is closer to 0 means the population
is closer to WT by molecular features, and an
average at 0.5 means the population is not biased
toward WT or KO features. It is clear that in layer 5,
all synapse classes, by molecular features, appear
KO, and after fenobam treatment all synapses
classes appear more WT.
(B) Graph of average probabilities for individual
synapse classes in layer 4 of the cortex. Here it
is apparent that VGluT2-containing synapses are
more KO by molecular features than VGluT1 syn-
apses, and VGluT2-containing synapses are not
normalized to WT by fenobam treatment. Also note
the more WT average probabilities of FXR2P-con-
taining synapses than synapses that do not. Sig-
nificance is calculated using Kruskal-Wallis tests,
and the p values are adjusted via FDR test. q < 0.01.
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Diverse Synaptic Response to Fmr1 KO and Its Rescuewhich FMRP affects the guidance and wiring of thalamic axons
(Christie et al., 2009). Thus, FMRP loss during development
might cause a wiring deficit in the thalamocortical circuits that
are insensitive to the postdevelopmental application of fenobam,
as was revealed by our data. Moreover, it is important to note
that this current study, while extensive in its synaptic coverage,
is only a snapshot in time of adult (4 month) somatosensory cor-
tex. We know that during development there are critical periods
during which the connectivity of the brain is irrevocably altered.
FMRP loss is lifelong; thus, one would expect there to be a
buildup of connectivity abnormalities imprinted by direct and
compensatory mechanisms during these critical periods. This
suggests that there may be time-dependent therapeutic win-
dows and long-range, brain-wide wiring deficits in Fmr1 KO
mice that are currently unknown.
Thus, large-scale, single-synapse analysis demonstrates the
extraordinary complexity and diversity in responses to FMRP
loss. The quantification of the complex nature of synaptic
changes in FXS illustrates the difficulty in designing treatments
for neurodevelopmental disorders, as any rescue attempted
beyond the initial perturbation (FMRP loss), such as mGluR5
antagonism, immediately becomes a process of dealing with a
cascade of direct and indirect molecular interactions. It is in
this complex interaction of cells and molecules that the type of
physiologically grounded, phenotype-based analysis presented
in this paper become invaluable, as it provides a method for
quantifying the complex system-level response of the nervous
system to brain-wide perturbations.
Moreover, the demonstration that FXS, a monogenic disorder,
causes a highly diverse set of synaptic phenotypes suggests that
other cognitive disorders with still more complex genetic and
environmental etiologies (such autism spectrum, neurodegener-
ative, and psychiatric disorders) are also likely to possess aNediverse range of molecular abnormalities across synapse popu-
lations. More importantly, these data demonstrate that synapses
are not all the same. Molecular and physiological mechanisms
discovered in one cell type, in one region of the brain, do not
necessarily generalize across all cells in the brain. Diseases, as
well as pharmaceuticals, will have differential impacts on cells
and synapses dependent upon the location and identity of their
cellular neighborhoods. Thus, it is important, moving forward,
to understand neurological diseases and their treatment in terms
of how cellular systems interact across circuits and regions on a
molecular level.
EXPERIMENTAL PROCEDURES
Preparation of AT Ribbon Arrays and Immunohistochemistry
Tissue preparation, array creation, and immunohistochemistry are described
in detail in previous publications (Micheva and Smith, 2007).
Primary Antibodies
For a detailed discussion of the antibodies used in this study and the vetting of
those antibodies, see the Supplemental Experimental Procedures.
Microscopy
Wide-field imaging of ribbons were accomplished on a Zeiss Axio
Imager.Z1 Upright Fluorescence Microscope with motorized stage and Axio-
cam HR Digital Camera, as previously described (Wang and Smith, 2012). A
position list was generated for each ribbon array of ultrathin sections using
custom software modules written for Axiovision. Single fields of view were
imaged for each position in the position list using a Zeiss 633 /1.4 NA Plan
Apochromat objective.
Image Registration and Computational Processing
AT data matrixes were registered and analyzed through a combination of
FIJI plug-ins and proprietary Matlab (Mathworks) functions (for a detailed
description of the computational pipeline, see Supplemental Experimental
Procedures).uron 84, 1273–1286, December 17, 2014 ª2014 Elsevier Inc. 1283
Neuron
Diverse Synaptic Response to Fmr1 KO and Its RescueRegression Analysis and Statistics
Regression analyses and significance statistics were performed using a com-
bination of Matlab native functions and custom scripts (see Supplemental
Experimental Procedures). Multiple comparison errors in p values are
controlled via Benjamini-Hochberg false discovery rate correction in Matlab
using third party developed functions (see Supplemental Experimental
Procedures).
Drug Treatment
Male 4 month of age, FMRP KO mice (C57BL/6) and WT mice were fed feno-
bam-supplemented food (100 mg fenobam/kg body weight) on a daily basis
for two weeks. After two weeks the animals were sacrificed and the brains
were prepared for array tomography. Animals were housed and handled in
accordance with protocols approved by the Administrative Panel on Labora-
tory Animal Care (APLAC) of Stanford University.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, one table, and Supple-
mental Experimental Procedures and can be found with this article online at
http://dx.doi.org/10.1016/j.neuron.2014.11.016.
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